Scopus: 1 cites, Google Scholar: cites,
Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
Dekker, Alain D. (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Vermeiren, Yannick (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Carmona-Iragui, Maria (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain)
Benejam, Bessy (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain)
Videla, Laura (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain)
Gelpi, Ellen (Neurological Tissue Bank—Biobanc, Hospital Clinic Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain)
Aerts, Tony (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Van Dam, Debby (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Fernández, Susana (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain)
Lleó Bisa, Alberto (Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain)
Videla, Sebastian (Faculty of Health and Life Sciences, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain)
Sieben, Anne (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Martin, Jean-Jacques (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium)
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau)
Fortea, Juan (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain)
De Deyn, Peter P. (Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium)

Data: 2017
Resum: People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Noradrenaline, adrenaline, and their metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG); dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid; and serotonin and its metabolite 5-hydroxyindoleacetic acid were quantified in 15 brain regions of DS without AD (DS, n = 4), DS with AD (DS+AD, n = 17), early-onset AD (EOAD, n = 11) patients, and healthy non-DS controls (n = 10) in the general population. Moreover, monoaminergic concentrations were determined in cerebrospinal fluid (CSF)/plasma samples of DS (n = 37/149), DS with prodromal AD (DS+pAD, n = 13/36), and DS+AD (n = 18/40). In brain, noradrenergic and serotonergic compounds were overall reduced in DS+AD versus EOAD, while the dopaminergic system showed a bidirectional change. For DS versus non-DS controls, significantly decreased MHPG levels were noted in various brain regions, though to a lesser extent than for DS+AD versus EOAD. Apart from DOPAC, CSF/plasma concentrations were not altered between groups. Monoamine neurotransmitters and metabolites were evidently impacted in DS, DS+AD, and EOAD. DS and DS+AD presented a remarkably similar monoaminergic profile, possibly related to early deposition of amyloid pathology in DS. To confirm whether monoaminergic alterations are indeed due to early amyloid β accumulation, future avenues include positron emission tomography studies of monoaminergic neurotransmission in relation to amyloid deposition, as well as relating monoaminergic concentrations to CSF/plasma levels of amyloid β and tau within individuals.
Nota: Altres ajuts: Fundacio Bancaria La Caixa, Marató de TV3 (20141210), Grifols Foundation, Generalitat de Catalunya 2014SGR-0235,Fundació Catalana de Sındrome de Down (FCSD), Interuniversity Poles of Attraction of the Belgian Federal Science Policy Office/IAP P7/16, Belgian Foundation for Alzheimer Research/SAO-FRA 15002.
Nota: Número d'acord de subvenció ISCIII/CM14-00029
Nota: Número d'acord de subvenció ISCIII/PI13-01532
Nota: Número d'acord de subvenció ISCIII/PI11-02425
Nota: Número d'acord de subvenció ISCIII/PI14-01126
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Matèria: Alzheimer's disease ; Cerebrospinal fluid ; Dementia ; Dopamine ; Down syndrome ; Monoamines ; MHPG ; Neurotransmitter ; Noradrenaline ; Plasma ; Serotonin ; Trisomy 21
Publicat a: Alzheimer's Dementia : Diagnosis, Assessment Disease Monitoring, Vol. 10 (november 2017) , p. 99-111, ISSN 2352-8729

PMID: 29780859
DOI: 10.1016/j.dadm.2017.11.001


13 p, 787.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació Biomèdica Sant Pau
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-07-30, darrera modificació el 2019-03-27



   Favorit i Compartir